Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Arterial Thrombosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    127 result(s) found for: Arterial Thrombosis. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2005-005524-13 Sponsor Protocol Number: I-ICRNS-005-PRCLD-DVT-01 Start Date*: 2006-03-22
    Sponsor Name:CRINOS S.p.A.
    Full Title: Defibrotide in the prevention of recurrences in venous thrombosis: DEPRIVE. A randomised, multicentre, European, double blind, parallel group study, to assess the efficacy and tolerability of defib...
    Medical condition: DVT and PE are part of the same disease that can be defined Venous Thromboembolism (VTE). Treatment of the acute phases is well established: LMWH during the first days and OAT for 3-12 months. Afte...
    Disease: Version SOC Term Classification Code Term Level
    10051055 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-006946-32 Sponsor Protocol Number: D5130C00048 Start Date*: 2007-10-04
    Sponsor Name:AstraZeneca AB, European Regulatory Affairs
    Full Title: A Multi-centre Randomised, Double-blind, Double-dummy Parallel Group Study of the Onset and Offset of the Antiplatelet Effects of AZD6140 Compared with Clopidogrel and Placebo With Aspirin as Backg...
    Medical condition: Arterial thrombosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003178 Arterial thrombosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004575-13 Sponsor Protocol Number: TRAPS-1.5 Start Date*: 2014-10-29
    Sponsor Name:Dipartimento di Scienze Cardiologiche, Toraciche e Vascolari-Università di Padova
    Full Title: A prospective, randomized clinical trial comparing Rivaroxaban vs warfarin in high risk patients with antiphospholipid syndrome (TRAPS).
    Medical condition: THROMBOEMBOLISM PREVENTION
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000539-29 Sponsor Protocol Number: 2018.02.08 Start Date*: 2018-12-11
    Sponsor Name:Hamilton Health Sciences Corporation
    Full Title: PeriOperative ISchemic Evaluation-3 (POISE-3) Trial
    Medical condition: The occurrence of life-threatening, major, and critical organ bleeding, and, major arterial and venous thrombosis in patients undergoing noncardiac surgery. And for patients in the blood pressure m...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10043611 Thrombosis arterial LLT
    21.0 100000004866 10043640 Thrombosis venous LLT
    23.1 100000004863 10051014 Post procedural bleeding LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) DK (Completed) AT (Completed) NL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002433-31 Sponsor Protocol Number: 29BRC17.0125 Start Date*: 2017-09-13
    Sponsor Name:CHRU de BREST
    Full Title: REduced dose versus full-dose of direct oral anticoagulant after uNprOvoked Venous thromboEmbolism. The RENOVE open-label, randomized, controlled trial
    Medical condition: Patients with indications for long-term anticoagulation after VTE (i.e.; symptomatic PE or proximal DVT) initially treated during 6 to 12 months with anticoagulant therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10047249 Venous thrombosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002298-25 Sponsor Protocol Number: 20203331 Start Date*: 2021-09-15
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario La Paz (FIBHULP)
    Full Title: A multicenter, adaptive, prospective, randomized trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-016475-29 Sponsor Protocol Number: RAD-09 Start Date*: 2010-03-11
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Treatment of advanced hepatocellular carcinoma (HCC) with portal vein thrombosis by hepatic intra-arterial injection of microspheres loaded with Yttrium-90 (Thera-Sphere)
    Medical condition: advanced hepatocellular carcinoma (HCC) with portal vein thrombosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024662 LLT
    9.1 10019713 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002385-74 Sponsor Protocol Number: BAY59-7939/17618 Start Date*: 2015-04-24
    Sponsor Name:Bayer HealthCare AG
    Full Title: 7-day study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in children from birth to less than 6 months with catheter-related arterial or venous ...
    Medical condition: Catheter related venous or arterial thrombosis
    Disease:
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) DE (Completed) NL (Completed) PL (Completed) FR (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002950-67 Sponsor Protocol Number: HA004 Start Date*: 2005-04-25
    Sponsor Name:Nuvelo, Inc.
    Full Title: Phase 3, Multi-center, Multi-National, Randomized, partical double-blind, Placebo controlled study to evaluate the efficacy and safety of Alfimeprase in subjects with acute peripheral arterial occl...
    Medical condition: Acute peripheral arterial occlusion (PAO)
    Disease: Version SOC Term Classification Code Term Level
    10062599
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) DE (Completed) AT (Completed) IT (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001709-21 Sponsor Protocol Number: 2020PI073 Start Date*: 2020-04-29
    Sponsor Name:CHRU de Nancy
    Full Title: Effectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolis...
    Medical condition: Prevention of thromboembolic events in hospitalised COVID-19 infected patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10014523 Embolism and thrombosis HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2022-001697-58 Sponsor Protocol Number: 2128/2021 Start Date*: 2022-12-20
    Sponsor Name:Medical University of Vienna
    Full Title: An investigation of clinical outcomes and inflammatory response to heparin free extracorporeal membrane oxygenation support during clinical lung transplantation – a prospective double-blind randomi...
    Medical condition: Intraoperative extra-corporeal membrane oxygenation during lung transplantation for end-stage lung disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004150-27 Sponsor Protocol Number: KAR0001HEARTCAT Start Date*: 2005-11-03
    Sponsor Name:Universitätsklinik für Kinder- und Jugendheilkunde
    Full Title: RANDOMIZED CONTROLLED TRIAL COMPARING TWO HEPARINIZATION PROTOCOLS FOR PROPHYLAXIS OF SHORT- AND LONG-TERM THROMBOTIC COMPLICATIONS OF PEDIATRIC CARDIAC CATHETERIZATION The HEARTCAT – Study (HEpar...
    Medical condition: Patients requiring diagnostic or interventional cardiac catheterisation (without Stent, device or catheter ablation)
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005375-14 Sponsor Protocol Number: TS-104 Start Date*: 2013-06-03
    Sponsor Name:Biocompatibles UK Ltd
    Full Title: A prospective randomized clinical trial on 90Yttrium trans-arterial radio-Embolization (Therasphere) vs. standard of care (sorafenib) for the treatment of advanced Hepatocellular carcinoma (HCC) ...
    Medical condition: Advanced Hepatocellular Carcinoma (HCC) with Portal Vein Thrombosis (PVT)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    17.0 10019805 - Hepatobiliary disorders 10036206 Portal vein thrombosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000997-53 Sponsor Protocol Number: RF-2009-1546106 Start Date*: 2012-05-25
    Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
    Full Title: ANTIPLATELET TREATMENT FOR PREVENTION OF VASCULAR OUTCOMES IN PAD PATIENTS UNDERGOING PERIPHERAL REVASCULARIZATION.
    Medical condition: Will be enrolled in the study patients suffering from intermittent claudication in whom resulted ineffective both pharmacological and workout therapy- Will be considered eligible patients aged 40-8...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10003209 Arteriopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000968-30 Sponsor Protocol Number: RC31/19/0509 Start Date*: 2021-04-13
    Sponsor Name:CHU Toulouse
    Full Title: ASPirin in Immune thRombocytopenia patients with cardiovascular disEase
    Medical condition: Immune thrombocytopenia with cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    23.0 10005329 - Blood and lymphatic system disorders 10083842 Immune thrombocytopenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002253-30 Sponsor Protocol Number: SVT-RUXO#2012 Start Date*: 2012-10-04
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI FIRENZE
    Full Title: A phase 2 study of Ruxolitinib in patients with splanchnic vein thrombosis associated with myeloproliferative neoplasm
    Medical condition: splanchnic vein thrombosis associated with myeloproliferative neoplasm
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10013238 Disorder myeloproliferative LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004913-11 Sponsor Protocol Number: 111075 Start Date*: 2021-02-18
    Sponsor Name:Radboudumc
    Full Title: genotype-guided strategy for antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease’
    Medical condition: Symptomatic or stable pheripheral artery disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004859-22 Sponsor Protocol Number: UF9888 Start Date*: 2018-04-12
    Sponsor Name:University Hospital of Monptellier
    Full Title: Treatment of hepatocellular carcinoma on child cirrhosis A/B7 by intra-arterial injection of a Lipiodol and Idarubicin emulsion : a multicentric single-arm phase II study
    Medical condition: The research hypothesis is that hepatic locoregional treatment without embolization, using a more cytotoxic anticancer molecule (Idarubicin) than those conventionally used, would be more effective.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003009-88 Sponsor Protocol Number: DU176b-E-U210 Start Date*: 2012-12-27
    Sponsor Name:Daiichi Sankyo Development Ltd
    Full Title: A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-CENTER STUDY OF ADDING EDOXABAN OR CLOPIDOGREL TO ASPIRIN TO MAINTAIN PATENCY IN SUBJECTS WITH PERIPHERAL ARTERIAL DISEASE FOLLOWING FEMOROPOPLIT...
    Medical condition: Edoxaban is being investigated for use in PAD subjects after femoropopliteal endovascular interventions with/without stent placement for the maintenance of patency and prevention of re-intervention.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004866 10067825 Peripheral arterial disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) NL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-006056-37 Sponsor Protocol Number: 1160.143 Start Date*: 2013-09-05
    Sponsor Name:Hamilton Health Sciences Corporation
    Full Title: A large, international, randomized, placebo-controlled trial to assess the impact of dabigatran (a direct thrombin inhibitor) and omeprazole (a proton-pump inhibitor) in patients suffering myocardi...
    Medical condition: MINS (myocardial injury after noncardiac surgery)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022117 - Injury, poisoning and procedural complications 10066592 Post procedural myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) IT (Completed) PT (Completed) ES (Completed) GB (Completed) AT (Completed) DE (Prematurely Ended) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:20:47 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA